BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Post Quarterly Sales of $50.59 Million

Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) to post $50.59 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $55.47 million and the lowest is $47.10 million. BioCryst Pharmaceuticals reported sales of $19.06 million in the same quarter last year, which indicates a positive year-over-year growth rate of 165.4%. The company is expected to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $268.91 million for the current financial year, with estimates ranging from $261.18 million to $278.91 million. For the next year, analysts expect that the firm will report sales of $379.63 million, with estimates ranging from $348.06 million to $429.32 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.09). The business had revenue of $47.16 million for the quarter, compared to the consensus estimate of $48.18 million.

BCRX has been the subject of several recent research reports. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 13th. Bank of America lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $21.00 to $14.00 in a research note on Monday, April 11th. Barclays cut BioCryst Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $22.00 to $13.00 in a research note on Monday, April 18th. Royal Bank of Canada dropped their price target on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 12th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, February 24th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.09.

NASDAQ BCRX traded down $0.38 during trading hours on Monday, hitting $9.29. The company had a trading volume of 4,747,773 shares, compared to its average volume of 6,670,730. The firm’s 50 day moving average is $14.62 and its 200 day moving average is $14.29. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -9.02 and a beta of 2.34. BioCryst Pharmaceuticals has a fifty-two week low of $9.25 and a fifty-two week high of $19.99.

In related news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total transaction of $92,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Helen M. Thackray sold 7,600 shares of the firm’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $16.20, for a total transaction of $123,120.00. Following the completion of the sale, the insider now owns 136,400 shares of the company’s stock, valued at approximately $2,209,680. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Large investors have recently bought and sold shares of the business. Hanseatic Management Services Inc. bought a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $91,000. DekaBank Deutsche Girozentrale raised its holdings in shares of BioCryst Pharmaceuticals by 10.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 73,765 shares of the biotechnology company’s stock worth $1,213,000 after acquiring an additional 6,700 shares during the period. Assenagon Asset Management S.A. lifted its position in BioCryst Pharmaceuticals by 435.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 70,844 shares of the biotechnology company’s stock valued at $1,152,000 after acquiring an additional 57,608 shares in the last quarter. Strs Ohio acquired a new position in BioCryst Pharmaceuticals in the 1st quarter worth $32,000. Finally, First Hawaiian Bank increased its holdings in BioCryst Pharmaceuticals by 68.2% during the 1st quarter. First Hawaiian Bank now owns 51,735 shares of the biotechnology company’s stock worth $841,000 after purchasing an additional 20,970 shares in the last quarter. 57.08% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.